Version 2.1.0.0

Abstract

Abstract: DESCRIPTION (provided by applicant): Developing strategies and products to prevent the spread of antibiotic resistance is a national priority. A significant contributing factor in the rise of antibiotic resistance is the use of antibiotics to treat diseases which are not life threatening. We propose to develop two novel anti-microbial agents, Nisin and Jenseniin P, to treat topical infections including acne, wounds, sores, and burns. Each year there are 5 million prescriptions for oral antibiotics and other drugs to treat acne. Hospital-acquired infections caused by just six common kinds of resistant bacteria costs at least $1.3 billion/year. This bactericin based product would have three characteristics. First, it would be a highly effective treatment of acne. Second, it would be inherently safe for use on human skin. Third, it would replace antibiotics that are known to select for resistance to Class I and II antibiotics used to treat life threatening human disease and therefore reduce the problem of antibiotic resistance. PROPOSED COMMERCIAL APPLICATION: This novel formulation would have both prophylactic and therapeutic use to replace existing acne controlling products. The market size is difficult to estimate both one product, Retin-A, has a $500 million market. Other applications of this product are also possible.

Thesaurus Terms:
antibiotic, drug design /synthesis /production, drug resistance, skin infection, topical drug application
acne, burn, wound

Institution:	IMMUCELL CORPORATION
	56 EVERGREEN DR
	PORTLAND, ME 04103
Fiscal Year:	2002
Department:
Project Start:	01-MAR-2002
Project End:	28-FEB-2003
ICD:	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
IRG:	ZRG1